These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 19421832

  • 1. Renal toxicity of targeted therapies.
    Kelly RJ, Billemont B, Rixe O.
    Target Oncol; 2009 Apr; 4(2):121-33. PubMed ID: 19421832
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Adverse effects of anticancer agents that target the VEGF pathway.
    Chen HX, Cleck JN.
    Nat Rev Clin Oncol; 2009 Aug; 6(8):465-77. PubMed ID: 19581909
    [Abstract] [Full Text] [Related]

  • 4. [Angiogenesis and renal cell carcinoma].
    Billemont B, Méric JB, Izzedine H, Taillade L, Sultan-Amar V, Rixe O.
    Bull Cancer; 2007 Jul; 94 Spec No():S232-40. PubMed ID: 17846009
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
    Rini BI.
    Clin Cancer Res; 2007 Feb 15; 13(4):1098-106. PubMed ID: 17317817
    [Abstract] [Full Text] [Related]

  • 7. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.
    Patel TV, Morgan JA, Demetri GD, George S, Maki RG, Quigley M, Humphreys BD.
    J Natl Cancer Inst; 2008 Feb 20; 100(4):282-4. PubMed ID: 18270341
    [No Abstract] [Full Text] [Related]

  • 8. Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.
    Snider KL, Maitland ML.
    Target Oncol; 2009 Apr 20; 4(2):67-76. PubMed ID: 19373440
    [Abstract] [Full Text] [Related]

  • 9. [Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib].
    Wollenberg A, Staehler M, Eames T.
    Hautarzt; 2010 Aug 20; 61(8):662-7. PubMed ID: 20631979
    [Abstract] [Full Text] [Related]

  • 10. American Society of Clinical Oncology--43rd annual meeting. Translating research into practice.
    Kibble A, Shumoogam J.
    IDrugs; 2007 Aug 20; 10(8):509-12. PubMed ID: 17665319
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?
    Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM.
    Oncologist; 2010 Aug 20; 15(2):130-41. PubMed ID: 20139170
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. VEGF inhibition and metastasis: possible implications for antiangiogenic therapy.
    English BC, Price DK, Figg WD.
    Cancer Biol Ther; 2009 Jul 20; 8(13):1214-25. PubMed ID: 19483467
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue.
    Chen MH.
    Curr Cardiol Rep; 2009 May 20; 11(3):167-74. PubMed ID: 19379636
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.